loader from loading.io

Dr. Ben Sessa - Preliminary Results from MDMA Assisted Therapy for Alcohol Use Disorder

Psychedelics Today

Release Date: 09/24/2019

PT504 – Rethinking Drug Education: From D.A.R.E. Scare Tactics to an Evidence-Based Approach, with Joey Lichter, Ph.D. show art PT504 – Rethinking Drug Education: From D.A.R.E. Scare Tactics to an Evidence-Based Approach, with Joey Lichter, Ph.D.

Psychedelics Today

In this episode, Joe interviews Joey Lichter, Ph.D.: professor in the Chemistry & Biochemistry department at Miami’s Florida International University, and one of the few professors in the U.S. teaching a course about psychedelics at the collegiate level. He talks about his path towards the course, the challenge of creating a curriculum that covers everything in a few months, and the importance of teaching young minds about psychedelics the right away; shifting drug education from the “Just say no!” D.A.R.E. model to a more balanced, honest, and evidence-based approach. He aims for...

info_outline
PT503 – Updates from MAPS: Current Initiatives, Psychedelic Science 2025, and Music as a Bridge, with Devon Phillips show art PT503 – Updates from MAPS: Current Initiatives, Psychedelic Science 2025, and Music as a Bridge, with Devon Phillips

Psychedelics Today

In this episode, Joe interviews Devon Phillips: community & partnerships officer for the Multidisciplinary Association for Psychedelic Studies (MAPS). Phillips works on strategies to tackle the questions: How do we responsibly mainstream psychedelics? And how do we get culture engaged? He's focusing on being the bridge to psychedelics outside of research, facilitating workshops and psychedelic coming-out stories at music festivals and conferences. He talks about harm reduction and drug checking at festivals, the concept of training big names to become trustworthy resources, the differences...

info_outline
PT502 – Preserving Psychedelic Legacies: Shulgin Farm and the Shulgin Archive Project, with Keeper Trout show art PT502 – Preserving Psychedelic Legacies: Shulgin Farm and the Shulgin Archive Project, with Keeper Trout

Psychedelics Today

In this episode, Joe interviews Keeper Trout: archivist, author, photographer, co-founder of the Cactus Conservation Institute, and creator of Trout’s Notes, a website compiling personal research and collected data to help ethnobotanical researchers. From an interest in cactus taxonomy, Sasha Shulgin urged Trout to go through his files, resulting in a friendship, and eventually, an 8-year project of digitizing all of these files into the ever-evolving Shulgin Archive. Trout discusses: His relationship with Sasha and The Shulgin Farm project, which aims to make the farm a community resource...

info_outline
PT501 – Women and Psychedelics, Microdosing, and the Challenges of Psychedelic Parenthood, with April Pride show art PT501 – Women and Psychedelics, Microdosing, and the Challenges of Psychedelic Parenthood, with April Pride

Psychedelics Today

In this episode, Alexa interviews April Pride: creative entrepreneur, veteran of the cannabis space, and now, founder of SetSet, an educational platform and podcast (picking up where The High Guide left off) for women curious about psychedelics. With Alexa about to embark on the journey of motherhood, she asks many of the questions parents working with psychedelics have to consider: How do you overcome the stigmas of being a psychedelic parent? How do you talk to your children about drugs? How do you know if a substance is ok to use during pregnancy? Pride discusses: Being dubbed “the weed...

info_outline
PT500 – Shulgin Farm and the Future of Psychedelic Drug Development, with Paul F. Daley, Ph.D. show art PT500 – Shulgin Farm and the Future of Psychedelic Drug Development, with Paul F. Daley, Ph.D.

Psychedelics Today

In this episode, Joe interviews Paul F. Daley, Ph.D., who worked with Sasha Shulgin in his lab for the last seven years of his life, helping him finish (and co-authoring) "The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds." He is now the co-founder, Chief Science Officer, and Director of Analytical Science at the Alexander Shulgin Research Institute (ASRI), focusing on the discovery and development of novel psychedelic compounds. While Sasha was passionate about self-experimentation, the Institute is aiming for the next step for these drugs: FDA approval.  ...

info_outline
PT499 – Osiris González Romero – Mesoamerican Psychedelics, Decolonization, and the Concept of an Ontological Turn show art PT499 – Osiris González Romero – Mesoamerican Psychedelics, Decolonization, and the Concept of an Ontological Turn

Psychedelics Today

In this episode, David interviews Osiris González Romero: philosopher and Postdoctoral researcher on cognitive freedom and psychedelic humanities at the University of Saskatchewan. Romero believes that our weakest point of research is our knowledge of Indigenous languages, and is focused on highlighting different cultural uses of psychedelics to better inform future drug policy. He’s currently studying more than 100 documents (including one over 400 years old) to establish an honest understanding of why peyote was ever banned. He discusses: Mesoamerican psychedelics and their relevance to...

info_outline
PT498 – Maria Mangini, Ph.D., FNP – Traversing the Psychedelic Landscape: From Esalen and Millbrook to the Future of Shulgin Farm show art PT498 – Maria Mangini, Ph.D., FNP – Traversing the Psychedelic Landscape: From Esalen and Millbrook to the Future of Shulgin Farm

Psychedelics Today

In this episode, Joe interviews Maria Mangini, Ph.D., FNP: researcher, educator, and midwife who has worked closely with many psychedelic innovators and was part of the original social network at Shulgin Farm – where this episode was recorded. She traces her journey from the influence of pioneers like the Wassons, Shulgins, and Grofs, and historic places like Esalen and Millbrook. She discusses: Her early experiences with the Grofs at Esalen and how she met the Shulgins Gregory Bateson guiding her to become a midwife The similarities between midwifery and psychedelic facilitation The unsung...

info_outline
PT497 – Wendy Tucker – Reflections from Shulgin Farm: Psychedelics, Legacy, and the Spirit of Discovery show art PT497 – Wendy Tucker – Reflections from Shulgin Farm: Psychedelics, Legacy, and the Spirit of Discovery

Psychedelics Today

In this episode, released on Ann Shulgin’s birthday, Joe interviews Wendy Tucker: daughter of Ann and stepdaughter to Alexander “Sasha” Shulgin. Recorded in Sasha’s old office, she recounts her formative years, giving an insider’s look into her Mother’s openness about psychedelics, working with Sasha in the lab, how the Shulgins made a perfect team, and watching a close-knit circle of self-experimenters start to form at Shulgin Farm – and keep coming back over the years. She talks about the energy infused into the property from the decades of research and gatherings, and how she...

info_outline
PT496 – Juan Pablo Cappello – Maintenance Doses and Recurring Revenue: The Ethics of At-Home Ketamine Therapy show art PT496 – Juan Pablo Cappello – Maintenance Doses and Recurring Revenue: The Ethics of At-Home Ketamine Therapy

Psychedelics Today

In this episode, Joe interviews Juan Pablo Cappello: co-founder and former CEO of Nue Life Health, whose assets were subsequently acquired by Beckley Waves. Cappello digs into his recent article which has been making waves across the psychedelic community: “.” He created Nue Life with the goal of helping a million people address the root cause of their anxiety, and while the company was successful, he began to see a problematic trend: that using ketamine while providing services of a mental health company is very expensive and resource-consuming, and as companies saw a large percentage of...

info_outline
PT495 – Dr. 1Drea Pennington Wasio – Self-Love, Narrative Therapy, and Post-Traumatic Growth show art PT495 – Dr. 1Drea Pennington Wasio – Self-Love, Narrative Therapy, and Post-Traumatic Growth

Psychedelics Today

In this episode, David interviews Dr. 1Drea Pennington Wasio: integrative physician, psychedelic-assisted therapy facilitator and psilocybin retreat leader, international speaker, podcaster, and author of several books, including "Sacred Medicine: Exploring The Psychedelic Hero’s Journey." She discusses her personal metamorphosis and name change inspired by a powerful ayahuasca experience, and how that moved her into a life more inspired by authenticity and self-love. She gives the details of her retreats, explains her PRISM sessions, and talks in depth about the magic of resiliency: How can...

info_outline
 
More Episodes

In this episode, Kyle and Joe interview Ben Sessa, a Consultant Psychiatrist. Ben comes on the show to talk about preliminary results from the first ever, MDMA assisted therapy for alcohol use disorder (AUD).

3 Key Points:

  1. Ben Sessa plays a role in leading the current MDMA assisted therapy study for alcohol use disorder, and shares preliminary results.
  2. In the current stage, out of the first 12 patients, 2 have turned back to drinking, 5 have stayed completely dry and another 5 who have had a drink or two but have not relapsed back to their typical levels of consumption.
  3. Most people with a long term substance addiction have a history of trauma. MDMA can help people feel safe, in order to work through and heal trauma.

Support the show

Navigating Psychedelics


Trip Journal                                               Integration Workbook


Show Notes

Preliminary Results

  • They had 13 people in the study, and they took data on 4 people
  • The first caveat in these results is that there was no blinding and no placebo in this study
    • There is no way to tell that it was solely the drug that resulted in the effects
  • In terms of tolerability, everyone preferred it to other treatment, there were no bad reactions to the MDMA, there were no negative reactions, it was a total success in terms of tolerability
  • In the current stage, out of the first 12 patients, 2 have turned back to drinking, 5 have stayed completely dry and another 5 who have had a drink or two but have not relapsed back to their typical levels of consumption
    • They did a similar study previous to this one except without the MDMA and they had 11 patients, 9 of them went back to their full level of consumption
  • They chose alcohol use disorder because it's so difficult to treat
  • All patients are recruits from local drug and alcohol services
    • Ben picks them up after they have detoxed, after they have been cured of the physical dependence, but when they have yet to be cured of the psychological dependence
  • They receive 2 dosing days within their 8 week therapy (usually weeks 3 and 6)
    • They do 125mg and then half that size dose 2 hours later, which sustains the high
  • Ben mentions that recruitment is difficult, a lot of people have a drinking problem, but they can't have patients that are depressed, suicidal, pregnant, epileptic, etc.

Future for the Study

  • Up until next March, they are continuing to take in new patients for the study to have more data
  • The next step is to have a randomized control study
  • This current study is sponsored by Imperial College of London
    • It's not a MAPS sponsored study, it's the first non MAPS, MDMA study
  • The main papers, with all the data are over a year and a half away from publishing

Addiction and Trauma

  • “MDMA addiction is as rare as a hen with teeth.” - Ben
  • “Most people with a long term substance addiction have a history of trauma.” - Ben
  • Trauma and PTSD is highly treatment resistant
  • There are certain drugs that inhibit fear response, such as alcohol, heroin, etc
    • They make you forget the pain but you can't work with them and do therapy with them, with MDMA you can
  • MDMA can help people feel safe, in order to work through and heal trauma
  • “We are all the products of our attachment relationships.” - Ben

Breaking Convention

  • This past year was the 5th one
  • There were 1300 attendees from all over the world
  • What's wonderful about Breaking Convention is how multidisciplinary it is
    • There's the guy in the gray suit in one room talking about high level neuroscience and a hippie with dreads in the other room talking about the spirits that live in the Salvia leaves
    • Ben says they work really hard to make that balance work
  • There's a lot of debate and conflict in the psychedelic movement right now,
    • Breaking Convention is very important for creating space for this debate

Looking ahead

  • Ben is looking into opening a clinic
  • He mentions academia is not his area of study, he is a clinician, but this research is an excuse to treat patients

Links

Breaking Convention


About Ben Sessa

Ben Sessa is a consultant psychiatrist in adult addictions, working part-time at Addaction in Weston-Super-Mare and is senior research fellow at Bristol, Cardiff and Imperial College London Universities, where he is currently taking time off clinical medical practice to study towards a PhD in MDMA Psychotherapy. He has specialist training as a child and adolescent psychiatrist and is interested in the developmental trajectory from child maltreatment to adult mental health disorders. Dr Sessa’s joint interests in psychotherapy, pharmacology and trauma have lead him towards researching the subject of drug-assisted psychotherapy using psychedelic adjuncts. He is the author of two books exploring psychedelic medicine; The Psychedelic Renaissance (2012) and To Fathom Hell or Soar Angelic (2015) and is currently conducting research with Imperial College London and Cardiff universities studying the potential role for MDMA-assisted therapy for the treatment of PTSD and alcohol dependence syndrome. Dr Sessa is outspoken on lobbying for change in the current system by which drugs are classified in the UK, believing a more progressive policy of regulation would reduce the harms of recreational drug use. He is a co-founder and director of the UK’s Breaking Convention conference.